{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:40Z","timestamp":1753891960722,"version":"3.41.2"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Pulmonary arterial hypertension (PAH) associated with congenital heart disease (PAH-CHD) occurs predominantly among patients with uncorrected congenital heart disease (CHD). It is an intractable problem to control PAH continuously and stably after an operation.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> 1) OPLS-DA combined with S-plot was used to retrospectively analyze the results of preoperative and postoperative PAH and 39 biochemical indicators of 235 patients admitted to Fuwai Yunnan Cardiovascular Hospital from January 2019 to December 2020. 2) Combined with Meta-analysis, the recurrence in postoperative PAH was analyzed in terms of operation factors, doses administered, and age factors.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> 1) 4 indicators (PAH, RBC, HGB, and CO<jats:sub>2<\/jats:sub>) that reflect the prognosis of patients had been found by OPLS-DA combined with S-plot. 2) The recurrence rate of postoperative PAH was 37.02%. The comprehensive therapeutic effect of interventional closure was better than that of surgical operation. PAH was not significantly higher again in patients who received either the instruction dose or the literature dose. Postoperative combination therapy (bosentan and sildenafil) was more effective than bosentan alone. Recovery after treatment was better in infants than in the other four age groups.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> OPLS-DA combined with S-plot was used for the first time to analyze clinical examination data. In this study, this method proved to be a feasible method for analyzing clinical data We recommend interventional closure as the first choice for patients with PAH-CHD. For postoperative oral therapy, we recommend the combination therapy (bosentan with sildenafil). To prevent the recurrence, the dose should be strictly prescribed according to the instructions, literature, or body surface area converted. Moreover, we recommend treatment at a young age in these patients.<\/jats:p>","DOI":"10.3389\/fphar.2021.660405","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T11:28:28Z","timestamp":1619695708000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Inadequate Dosage May Lead to the Recurrence of Postoperative Pulmonary Hypertension in Patients With Congenital Heart Disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Xinmei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Te","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"yty033","DOI":"10.1093\/ehjcr\/yty033","article-title":"Treat-and-repair Strategy is a Feasible Therapeutic Choice in Adult Patients with Severe Pulmonary Arterial Hypertension Associated with a Ventricular Septal Defect: Case Series","volume":"2","author":"Akagi","year":"2018","journal-title":"Eur. Heart J. Case Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1093\/icvts\/ivt353","article-title":"Etc. Perioperative Sildenafil Therapy for Pulmonary Hypertension in Infants Undergoing Congenital Cardiac Defect Closure[J]","volume":"17","author":"Ashraf","year":"2013","journal-title":"Interact Cardiovasc. Thorac. Surg."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.7655\/NYDXBNS20161236","article-title":"Clinical Analysis of Unclosed Ductus Arteriosus in Children with Severe Pulmonary Hypertension [J]","volume":"36","author":"Cao","year":"2016","journal-title":"J. Nanjing Med. Univ. (Natural Science)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12890-017-0374-x","article-title":"etc.Efficacy of 1, 5, and 20 Mg Oral Sildenafil in the Treatment of Adults with Pulmonary Arterial Hypertension: a Randomized, Double-Blind Study with Open-Label Extension[J]","volume":"17","author":"Carmine","year":"2017","journal-title":"BMC Pulm. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3969\/j.issn.1674-4721.2017.28.012","article-title":"Changes in Pulmonary Artery Pressure after Atrial Septal Defect Closure in Adults [J]","volume":"24","author":"Chao","year":"2017","journal-title":"Chin. J. Contemp. Med."},{"key":"B6","first-page":"19","article-title":"etc.Targeted-drug Combined with Interventional Therapy in the Treatment of Congenital Heart Disease Complicated with Severe Pulmonary Hypertension [J]","volume":"3","author":"Cheng","year":"2014","journal-title":"J. Cardiovasc. Surg."},{"key":"B7","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s00392-005-0266-6","article-title":"Initial Experience with Bosentan (Tracleer) as Treatment for Pulmonary Arterial Hypertension (PAH) Due to Congenital Heart Disease in Infants and Young Children","volume":"94","author":"Gilbert","year":"2005","journal-title":"ZS Kardiologie"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1542\/peds.2005-0523","article-title":"Oral Sildenafil in Infants with Persistent Pulmonary Hypertension of the Newborn: a Pilot Randomized Blinded study.[J]","volume":"117","author":"Hernando","year":"2006","journal-title":"Pediatrics"},{"volume-title":"Interventional Therapy for Patients with Atrial Septal Defect and Moderate to Severe Pulmonary Hypertension: A Follow-Up Study [D]","year":"2013","author":"Jing","key":"B10"},{"key":"B9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3969\/j.issn.1007-5062.2016.04.011","article-title":"Clinical Study on Diagnostic Treatment of Congenital Heart Disease Complicated with Severe Pulmonary Hypertension [J]","volume":"35","author":"Jing","year":"2016","journal-title":"J. Cardiopulmonary Vasc. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"CD005494","DOI":"10.1002\/14651858.CD005494.pub4","article-title":"Sildenafil for Pulmonary Hypertension in Neonates","volume":"8","author":"Kelly","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"381787","DOI":"10.1155\/2011\/381787","article-title":"Pulmonary Hypertension Related to Left-Sided Cardiac Pathology[J]","volume":"2011","author":"Kiefer","year":"2011","journal-title":"Pulm. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3969\/j.issn.1672-3384.2020.01.015","article-title":"Meta-analysis of Bosentan Combined with Sildenafil in the Treatment of Pulmonary Hypertension [J]","volume":"18","author":"Li","year":"2020","journal-title":"J. Clin. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3389\/fphar.2020.00400","article-title":"Combined Methods (Formal Adjusted Indirect Comparison, Meta-Analysis and Principal Component Analysis) Comparisons of the Safety and Efficacy of Ambrisentan, Bosentan, and Sildenafil in the Patients with Pulmonary Arterial Hypertension","volume":"11","author":"Li","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B15","first-page":"4","volume-title":"Practical Pediatric Drug Dose Survey Manual [M]","author":"Li","year":"2010"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","article-title":"ACCF\/AHA 2009 Expert Consensus Document on Pulmonary Hypertension","volume":"53","author":"Mclaughlin","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.jtcvs.2011.02.028","article-title":"Impact of Pulmonary Hypertension on Outcomes after Aortic Valve Replacement for Aortic Valve Stenosis","volume":"141","author":"Melby","year":"2011","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"B18","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/jp.2011.157","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Prospective Study of Bosentan for the Treatment of Persistent Pulmonary Hypertension of the Newborn","volume":"32","author":"Mohamed","year":"2012","journal-title":"J. Perinatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"CD010531","DOI":"10.1002\/14651858.CD010531.pub2","article-title":"Endothelin Receptor Antagonists for Persistent Pulmonary Hypertension in Term and Late Preterm Infants","author":"More","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1183\/13993003.01032-2015","article-title":"Etc. 2015 ESC\/ERS Guidelines Fro the Diagnosis and Treatment of Pulmonary Hypertension[J]","volume":"37","author":"Nazzareno","year":"2016","journal-title":"Eur. Heart J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3233\/NPM-16161","article-title":"Etc. Effect of Early Adjunctive Use of Oral Sildenafil and Inhaled Nitric Oxide on the Outcome of Pulmonary Hypertension in Newborn Infants. A Feasibility Study[J]","volume":"9","author":"Omar","year":"2016","journal-title":"J. Neonatal-Perinatal Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1161\/CIRCULATIONAHA.110.016667","article-title":"etc.A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children with Pulmonary Arterial Hypertension[J]","volume":"7","author":"Robyn","year":"2011","journal-title":"Pediatr. Cardiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/tropej\/fmq091","article-title":"Etc. A Comparison of Magnesium Sulphate and Sildenafil in the Treatment of the Newborns with Persistent Pulmonary Hypertension: A Randomized Controlled Trial[J]","volume":"57","author":"Sinan","year":"2011","journal-title":"J. Trop. Pediatr."},{"key":"B24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jpeds.2016.06.078","article-title":"Bosentan as Adjunctive Therapy for Persistent Pulmonary Hypertension of the Newborn: Results of the Randomized Multicenter Placebo-Controlled Exploratory Trial","volume":"177","author":"Steinhorn","year":"2016","journal-title":"J. Pediatr."},{"key":"B25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3969\/j.issn.1004-8812.2016.02.003","article-title":"A Follow-Up Study of Left Heart Function after Patent Ductus Arteriosus Closure by Transthoracic Echocardiography [J]","volume":"24","author":"Sun","year":"2016","journal-title":"Chin. J. Interv. Cardiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jccase.2017.03.005","article-title":"Improvement of Pulmonary Arterial Hypertension Following Medication and Shunt Closure in a BMPR2 Mutation Carrier with Atrial Septal Defect","volume":"16","author":"Suzuki","year":"2017","journal-title":"J. Cardiol. Cases"},{"key":"B27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3969\/j.issn.1007-5062.2020.01.005","article-title":"Interventional Treatment and Follow-Up Study of Adults with Unclosed Ductus Arteriosus and Severe Pulmonary Hypertension [J]","volume":"39","author":"Wang","year":"2020","journal-title":"J. Cardiopulmonary Vasc. Dis."},{"volume-title":"Scale: The Universal Laws of Growth, Innovation, Sustainability, and the Pace of Life in Organisms,cities, Economies, and companies[M]","year":"2018","author":"West","key":"B28"},{"key":"B29","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1097\/CM9.0000000000000145","article-title":"Predictors of Operability in Children with Severe Pulmonary Hypertension Associated with Congenital Heart Disease","volume":"132","author":"Xi","year":"2019","journal-title":"Chin. Med. J."},{"key":"B30","first-page":"43","article-title":"Clinical Observation of Sildenafil in Treatment of Pulmonary Hypertension after Surgery for Congenital Heart Disease [J]","volume":"34","author":"Yang","year":"2014","journal-title":"J. Clin. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3969\/j.issn.1000-744X.2016.01.006","article-title":"etc.Comparison of Pulmonary Arterial Pressure and Blood Pressure before and after Patent Ductus Arteriosus Interventional Closure [J]","volume":"40","author":"Zhang","year":"2016","journal-title":"Guizhou Med. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3969\/j.issn.1008-0074.2012.04.23","article-title":"Etc. Study on Changes of Pulmonary Artery Pressure after Interventional Treatment of Patent Ductus Arteriosus [J]","volume":"21","author":"Zhang","year":"2012","journal-title":"J. Cardiovasc. Rehabil. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/00498254.2017.1306660","article-title":"Metabolic Map of Osthole and its Effect on Lipids","volume":"48","author":"Zhao","year":"2017","journal-title":"Xenobiotica"},{"volume-title":"Follow-up Study after Unclosed Ductus Arteriosus and Pulmonary Hypertension Closure [D]","year":"2013","author":"Zhao","key":"B34"},{"key":"B35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ahj.2018.03.020","article-title":"The Prevalence of Pulmonary Arterial Hypertension before and after Atrial Septal Defect Closure at Adult Age: A Systematic Review","volume":"201","author":"Zwijnenburg","year":"2018","journal-title":"Am. Heart J."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.660405\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T11:28:42Z","timestamp":1619695722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.660405\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":35,"alternative-id":["10.3389\/fphar.2021.660405"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.660405","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2021,4,29]]},"article-number":"660405"}}